» Authors » S Michael Gharacholou

S Michael Gharacholou

Explore the profile of S Michael Gharacholou including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 47
Citations 513
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Seby R, Umadat G, Espinosa S, Reddy P, Parikh P, Ray J, et al.
JACC Case Rep . 2025 Jan; 29(24):102843. PMID: 39822641
Papillary fibroelastomas (PFEs) are primary cardiac tumors associated with significant embolic risk. Surgical excision or medical therapy with antiplatelets and/or anticoagulants have been the treatment options for symptomatic patients. This...
2.
Ola O, Gharacholou S, Deshmukh A, Valverde A, Scott C, Lee A, et al.
J Interv Card Electrophysiol . 2024 Sep; PMID: 39325317
Background: Limited data exist on outcomes of atrial fibrillation (AF) catheter ablation based on hospital setting and, specifically, the availability of onsite cardiothoracic surgery (CTS). We aimed to describe the...
3.
Ijioma N, Gharacholou S, Lilly S
JACC Adv . 2024 Jun; 3(5):100926. PMID: 38939634
No abstract available.
4.
Schneider A, Gharacholou S
Tex Heart Inst J . 2024 May; 51(1). PMID: 38722191
A male patient presented with cardiac arrest attributed to anterior ST-segment elevation myocardial infarction from type 1 spontaneous coronary artery dissection. Subsequent imaging confirmed fibromuscular dysplasia in noncoronary arterial segments....
5.
Knott J, Ola O, De Michieli L, Akula A, Yang E, Gharacholou S, et al.
Mayo Clin Proc . 2024 Mar; 99(9):1435-1442. PMID: 38493402
Objective: To evaluate the diagnostic performance of the previously recommended baseline high-sensitivity cardiac troponin T (hs-cTnT) thresholds of 52 and 100 ng/L in identifying patients at high risk of acute...
6.
Jhawar N, Prasad A, Gharacholou S
Case Rep Cardiol . 2023 Aug; 2023:6626263. PMID: 37645685
Ischemic symptoms may be explained by a multitude of coronary pathologies, including coronary artery tortuosity, atherosclerosis, fibromuscular dysplasia, vasculitis, coronary vasospasm, or microvascular disease. We present an unusual case of...
7.
Cortes P, Zeng J, Karime C, Lewis M, Gharacholou S, Antwi S, et al.
Gastrointest Endosc . 2023 Aug; 99(1):10-20.e6. PMID: 37579980
Background And Aims: The management of dual anti-platelet therapy after percutaneous coronary intervention (PCI) and GI bleeding (GIB) remains a clinical dilemma. We sought to identify predictors of GIB and...
8.
Umadat G, Ray J, Cornell L, Pillai D, Gharacholou S
Am J Cardiol . 2022 Dec; 188:68-79. PMID: 36473307
Cardiovascular disease is the leading cause of mortality among breast cancer survivors. Anthracyclines and trastuzumab have been associated with an increased risk of cardiotoxicity, requiring close follow-up for signs of...
9.
Sandoval Y, Lewis B, Mehta R, Ola O, Knott J, De Michieli L, et al.
Circulation . 2022 May; 145(23):1708-1719. PMID: 35535607
Background: There are good data to support using a single high-sensitivity cardiac troponin T (hs-cTnT) below the limit of detection of 5 ng/L to exclude acute myocardial infarction. Per the...
10.
Ghannam A, Gharacholou S, Ball C, Pollak P, Parikh P, Landolfo C, et al.
Am J Cardiol . 2022 Apr; 173:100-105. PMID: 35367046
Immunocompromised (IC) patients are at greater risk of adverse outcomes from cardiac surgery, and less invasive options for treating severe aortic stenosis among IC patients are often sought. However, despite...